Answers are grounded in this paper and cite their sources.
Cellular immunotherapy for myeloma has the unique potential both to potently kill the malignant clone and to evoke a memory response to protect from relapse. Understanding the complex interactions between the malignant clone and the microenvironment that promote immune escape is critical to evoke effective antimyeloma immunity. Tremendous progress has been made in the area of cancer vaccines and adoptive T-cell therapy in recent years. Careful study of the mechanisms of response and of immune escape will be critical to developing novel combination therapies and ultimately to improve outcomes for patients with myeloma.
No takes yet. Share an insight, caveat, or question.
Rosenblatt et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: